Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 7/20 | 0.68 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 5/20 | 0.68 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.68 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.68 |
| ▸ | KCNA5 | P22460 | 4/20 | 0.68 |
| ▸ | KCNE1 | P15382 | 1/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.65 |
| ▸ | HPGD | P15428 | 1/20 | 0.65 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.65 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.63 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.63 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.63 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.63 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.63 |
| ▸ | DRD1 | P21728 | 2/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL31327366 | 0.98 | CYP2D6 (0.65) | CYP2D6KCNH2CYP3A4CYP1A2CYP2C19 | |
| SCHEMBL2054235 | 0.98 | CYP2D6 (0.67) | CYP2D6KCNH2CYP3A4CYP1A2CYP2C19 | |
| Hydrochloric Acid SCHEMBL16107427 | 0.95 | CYP2D6 (0.64) | CYP2D6KCNH2CYP3A4CYP1A2CYP2C19 | |
| SCHEMBL1502253 | 0.93 | CYP2D6 (0.65) | CYP2D6KCNH2CYP3A4CYP1A2CYP2C19 | |
| SCHEMBL6824843 | 0.88 | CYP2D6 (0.71) | CYP2D6KCNH2CYP3A4CYP1A2CYP2C19 | |
| Carbamic Acid SCHEMBL17460399 | 0.88 | KMT2A (0.68) | CYP2D6KCNH2CYP3A4CYP1A2CYP2C19 | |
| Alcohol SCHEMBL29012312 | 0.88 | OPRD1 (0.62) | CYP2D6KCNH2CYP3A4CYP1A2CYP2C19 | |
| SCHEMBL13309488 | 0.88 | CYP2D6 (0.71) | CYP2D6KCNH2CYP3A4CYP1A2CYP2C19 | |
| SCHEMBL16226328 | 0.88 | ACHE (0.63) | CYP2D6KCNH2CYP3A4CYP1A2CYP2C19 | |
| SCHEMBL7442471 | 0.88 | CYP2D6 (0.55) | CYP2D6KCNH2CYP3A4CYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11161811-B2 | Process for preparing Mannich base quaternary ammonium salt high-temperature resistant corrosion inhibitor and applications thereof | SOUTHWEST PETROLEUM UNIVERSITY (CN) | 2021-11-02 | — | — | US | claimed |
| US-20200331856-A1 | PROCESS FOR PREPARING MANNICH BASE QUATERNARY AMMONIUM SALT HIGH-TEMPERATURE RESISTANT CORROSION INHIBITOR AND APPLICATIONS THEREOF | SOUTHWEST PETROLEUM UNIVERSITY (CN) | 2020-10-22 | — | — | US | claimed |
| CN-109810040-B | Preparation method and application of Mannich base quaternary ammonium salt high-temperature-resistant acidizing corrosion inhibitor | 西南石油大学 | 2020-02-18 | — | — | CN | claimed |
| CN-109810040-A | A kind of preparation method and application of Mannich base quaternary ammonium salt high temperature resistant acidification corrosion inhibitor | 西南石油大学 | 2019-05-28 | — | — | CN | claimed |
| CN-1067385-C | Novel substituted piperidines useful for the treatment of allergic diseases | MERRELL DOW PHARMA (US) | 2001-06-20 | — | — | CN | claimed |
| CN-1158612-A | Novel substituted piperidines for the treatment of allergic diseases | MERRELL DOW PHARMA (US) | 1997-09-03 | — | — | CN | claimed |
| EP-0390718-A1 | Process for preparing new 1-diphenylmethylpiperidine derivatives | FABRICA ESPANOLA DE PRODUCTOS QUIMICOS Y FARMACEUTICOS, S.A. (FAES) (ES) | 1990-10-03 | — | — | EP | claimed |
| US-12515973-B1 | Scale treatment in geothermal or extremely high temperature wells | HALLIBURTON ENERGY SERVICES, INC. (US) | 2026-01-06 | — | — | US | disclosed |
| CN-120000749-A | Traditional Chinese medicine composition for treating idiopathic pulmonary fibrosis as well as preparation method and application thereof | 广州中医药大学第一附属医院 | 2025-05-16 | — | — | CN | disclosed |
| US-20250084091-A1 | INHIBITORS OF SARS-COV-2 | TEXAS A & M UNIV SYS (US) | 2025-03-13 | — | — | US | disclosed |
| US-20250084091-A1 | INHIBITORS OF SARS-COV-2 | TEXAS A & M UNIV SYS (US) | 2025-03-13 | — | — | US | disclosed |
| US-20240399360-A1 | DEVICES AND METHODS FOR CREATING TRANSCELLULAR PORES | GEORGIA TECH RES INST (US) | 2024-12-05 | — | — | US | disclosed |
| CN-113950477-B | Granulin precursor modulators and methods of use thereof | 阿库达医疗公司 | 2024-07-05 | — | — | CN | disclosed |
| EP-0390718-A1 | Process for preparing new 1-diphenylmethylpiperidine derivatives | FABRICA ESPANOLA DE PRODUCTOS QUIMICOS Y FARMACEUTICOS, S.A. (FAES) (ES) | 1990-10-03 | — | — | EP | disclosed |
| EP-0390718-A1 | Process for preparing new 1-diphenylmethylpiperidine derivatives | FABRICA ESPANOLA DE PRODUCTOS QUIMICOS Y FARMACEUTICOS, S.A. (FAES) (ES) | 1990-10-03 | — | — | EP | disclosed |
| EP-0183216-B1 | N-(ARALKOXYBENZYL)-4(BENZHYDRYL) PIPERIDINES | G.D. Searle & Co. (US) | 1989-07-19 | — | — | EP | disclosed |
| US-4673684-A | Amide derivatives and 5-lipoxygenase inhibitors containing the same as an active ingredient | TERUMO CORPORATION (JP) | 1987-06-16 | — | — | US | disclosed |
| US-4650874-A | CARDIOVASCULAR AGENTS | G. D. SEARLE & CO. (US) | 1987-03-17 | — | — | US | disclosed |
| EP-0183216-A1 | N-(Aralkoxybenzyl)-4(benzhydryl) piperidines | G.D. Searle & Co. (US) | 1986-06-04 | — | — | EP | disclosed |
| EP-0157420-A2 | Amide derivatives and 5-lipoxygenase inhibitors containing the same as an active ingredient | TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION (JP) | 1985-10-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250084091-A1 | INHIBITORS OF SARS-COV-2 | ACE2, ACE, TMPRSS2 | CYP2D6 125/4885KCNH2 1060/4885CYP3A4 172/4885 |
| US-11161811-B2 | Process for preparing Mannich base quaternary ammonium salt high-temperature resistant corrosion inhibitor and applications thereof | DDC, TYR, ABL1 | CYP2D6 3256/4885KCNH2 43/4885CYP3A4 2751/4885 |
| US-20200331856-A1 | PROCESS FOR PREPARING MANNICH BASE QUATERNARY AMMONIUM SALT HIGH-TEMPERATURE RESISTANT CORROSION INHIBITOR AND APPLICATIONS THEREOF | DDC, TYR, ABL1 | CYP2D6 3256/4885KCNH2 43/4885CYP3A4 2751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.